Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Multiple Sclerosis ; 16 (2010), 12. - S. 1507-1512. - ISSN 1352-4585. - eISSN 1477-0970
- Schlagwort
-
Hirnkrankheit
Neuropsychiatrie
Nervenkrankheit
- Ereignis
-
Veröffentlichung
- (wo)
-
Konstanz
- (wer)
-
Bibliothek der Universität Konstanz
- (wann)
-
2014
- Urheber
-
Heesen, Christoph
Kleiter, Ingo Wolfram
Nguyen, Franziska
Schäffler, Nina
Kasper, Jürgen
Köpke, Sascha
Gaissmaier, Wolfgang
- URN
-
urn:nbn:de:bsz:352-280329
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:57 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Heesen, Christoph
- Kleiter, Ingo Wolfram
- Nguyen, Franziska
- Schäffler, Nina
- Kasper, Jürgen
- Köpke, Sascha
- Gaissmaier, Wolfgang
- Bibliothek der Universität Konstanz
Entstanden
- 2014
Ähnliche Objekte (12)
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4
Early spinal cord pseudoatrophy in interferon‐beta‐treated multiple sclerosis
Patterns of Th1/Th2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate
Emergency medical care of multiple sclerosis patients
Cognitive functions over the course of 1 year in multiple sclerosis patients treated with disease modifying therapies
Apheresis therapy in immunopathologically classified multiple sclerosis patients
Multiple sclerosis
Multiple sclerosis
Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients
Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4
Early spinal cord pseudoatrophy in interferon‐beta‐treated multiple sclerosis
Patterns of Th1/Th2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate
Emergency medical care of multiple sclerosis patients
Cognitive functions over the course of 1 year in multiple sclerosis patients treated with disease modifying therapies
Apheresis therapy in immunopathologically classified multiple sclerosis patients
Multiple sclerosis
Multiple sclerosis
Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients
Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4
Early spinal cord pseudoatrophy in interferon‐beta‐treated multiple sclerosis
Patterns of Th1/Th2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate
Emergency medical care of multiple sclerosis patients
Cognitive functions over the course of 1 year in multiple sclerosis patients treated with disease modifying therapies
Apheresis therapy in immunopathologically classified multiple sclerosis patients
Multiple sclerosis
Multiple sclerosis
Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients